Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more
Market Cap & Net Worth: Aarti Drugs Limited (AARTIDRUGS)
Aarti Drugs Limited (NSE:AARTIDRUGS) has a market capitalization of $352.15 Million (₹30.50 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #16474 globally and #735 in its home market, demonstrating a -7.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aarti Drugs Limited's stock price ₹334.15 by its total outstanding shares 91270000 (91.27 Million).
Aarti Drugs Limited Market Cap History: 2015 to 2026
Aarti Drugs Limited's market capitalization history from 2015 to 2026. Data shows growth from $151.34 Million to $352.15 Million (8.37% CAGR).
Index Memberships
Aarti Drugs Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$535.73 Billion | 0.03% | #358 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.32 Trillion | 0.01% | #554 of 750 |
Weight: Aarti Drugs Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aarti Drugs Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aarti Drugs Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Aarti Drugs Limited's market cap is 0.02 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.26x
Aarti Drugs Limited's market cap is 0.26 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $155.44 Million | $11.35 Billion | $687.25 Million | 0.01x | 0.23x |
| 2017 | $164.88 Million | $11.95 Billion | $805.63 Million | 0.01x | 0.20x |
| 2018 | $149.61 Million | $12.44 Billion | $823.07 Million | 0.01x | 0.18x |
| 2019 | $150.61 Million | $15.61 Billion | $897.51 Million | 0.01x | 0.17x |
| 2020 | $738.41 Million | $18.06 Billion | $1.41 Billion | 0.04x | 0.52x |
| 2021 | $570.60 Million | $21.55 Billion | $2.80 Billion | 0.03x | 0.20x |
| 2022 | $482.73 Million | $24.89 Billion | $2.05 Billion | 0.02x | 0.24x |
| 2023 | $514.57 Million | $27.16 Billion | $1.66 Billion | 0.02x | 0.31x |
| 2024 | $485.21 Million | $25.29 Billion | $1.71 Billion | 0.02x | 0.28x |
| 2025 | $433.83 Million | $23.87 Billion | $1.68 Billion | 0.02x | 0.26x |
Competitor Companies of AARTIDRUGS by Market Capitalization
Companies near Aarti Drugs Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Aarti Drugs Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Aarti Drugs Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Aarti Drugs Limited's market cap moved from $151.34 Million to $ 352.15 Million, with a yearly change of 8.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹352.15 Million | -18.83% |
| 2025 | ₹433.83 Million | -10.59% |
| 2024 | ₹485.21 Million | -5.71% |
| 2023 | ₹514.57 Million | +6.60% |
| 2022 | ₹482.73 Million | -15.40% |
| 2021 | ₹570.60 Million | -22.73% |
| 2020 | ₹738.41 Million | +390.28% |
| 2019 | ₹150.61 Million | +0.67% |
| 2018 | ₹149.61 Million | -9.26% |
| 2017 | ₹164.88 Million | +6.07% |
| 2016 | ₹155.44 Million | +2.71% |
| 2015 | ₹151.34 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Aarti Drugs Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $352.15 Million USD |
| MoneyControl | $352.15 Million USD |
| MarketWatch | $352.15 Million USD |
| marketcap.company | $352.15 Million USD |
| Reuters | $352.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.